Merck & Co. Inc.

NYS: MRK

GO
/marketstate/country/us

Market open

 --Real time quotes

Oct 27, 2021, 10:21 a.m.

MRK
/zigman2/quotes/209956077/composite

$

81.47

Change

-0.78 -0.95%

Volume

Volume 1.16m

Real time quotes

/zigman2/quotes/209956077/composite

Previous close

$ 82.25

$ 81.47

Change

-0.78 -0.95%

Day low

Day high

$81.33

$82.48

Open

52 week low

52 week high

$68.38

$84.56

Open

Company Description

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human ...

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Valuation

P/E Current

29.36

P/E Ratio (with extraordinary items)

37.23

P/E Ratio (without extraordinary items)

29.41

Price to Sales Ratio

4.33

Price to Book Ratio

8.18

Price to Cash Flow Ratio

20.27

Enterprise Value to EBITDA

14.34

Enterprise Value to Sales

4.80

Total Debt to Enterprise Value

0.14

Efficiency

Revenue/Employee

648,824.00

Income Per Employee

95,500.00

Receivables Turnover

6.56

Total Asset Turnover

0.55

Liquidity

Current Ratio

1.02

Quick Ratio

0.79

Cash Ratio

0.30

Profitability

Gross Margin

73.77

Operating Margin

26.16

Pretax Margin

18.31

Net Margin

14.72

Return on Assets

8.03

Return on Equity

27.59

Return on Total Capital

22.39

Return on Invested Capital

13.93

Capital Structure

Total Debt to Total Equity

132.14

Total Debt to Total Capital

56.92

Total Debt to Total Assets

36.53

Long-Term Debt to Equity

105.55

Long-Term Debt to Total Capital

45.47

Officers and Executives

Name Age Officer Since Title
Mr. Kenneth C. Frazier 65 1992 Chairman, President & Chief Executive Officer
Mr. Robert M. Davis 53 2014 Chief Financial Officer & Executive Vice President
Ms. Caroline A. Litchfield - 1990 Treasurer
Mr. Dave Williams - - Chief Information & Digital Officer
Ms. Sandy Tremps - 1988 Vice President-R&D IT CIO

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
05/10/2021 Franklin K. Clyburn
EVP & Pres ? Human Health
19,324   Disposition at $78.32 per share. 1,513,455
05/10/2021 Franklin K. Clyburn
EVP & Pres ? Human Health
19,324   Derivative/Non-derivative trans. at $0 per share. 0
05/04/2021 Franklin K. Clyburn
EVP & Pres ? Human Health
939   Derivative/Non-derivative trans. at $75.98 per share. 71,345
05/04/2021 Rita A. Karachun
Sr. VP Fince-Global Controller
416   Derivative/Non-derivative trans. at $75.98 per share. 31,607
05/04/2021 Jennifer Zachary
EVP, General Counsel
2,843   Derivative/Non-derivative trans. at $75.98 per share. 216,011
05/04/2021 Caroline A. Litchfield
EVP & CFO
489   Derivative/Non-derivative trans. at $75.98 per share. 37,154
05/04/2021 Dean Y. Li
Executive VP & President, MRL
238   Derivative/Non-derivative trans. at $75.98 per share. 18,083
05/04/2021 David Michael Williams
EVP,Chief Info&Digital Officer
143   Derivative/Non-derivative trans. at $75.98 per share. 10,865
05/04/2021 Lecointe Cephas Lisa
SVP Chief Ethics & Com Officer
238   Derivative/Non-derivative trans. at $75.98 per share. 18,083
05/04/2021 Franklin K. Clyburn
EVP & Pres ? Human Health
1,906   Derivative/Non-derivative trans. at $75.98 per share. 144,817
05/04/2021 Rita A. Karachun
Sr. VP Fince-Global Controller
1,212   Derivative/Non-derivative trans. at $75.98 per share. 92,087
05/04/2021 Jennifer Zachary
EVP, General Counsel
5,772   Derivative/Non-derivative trans. at $75.98 per share. 438,556
05/04/2021 Caroline A. Litchfield
EVP & CFO
1,039   Derivative/Non-derivative trans. at $75.98 per share. 78,943
05/04/2021 Dean Y. Li
Executive VP & President, MRL
694   Derivative/Non-derivative trans. at $75.98 per share. 52,730
05/04/2021 David Michael Williams
EVP,Chief Info&Digital Officer
417   Derivative/Non-derivative trans. at $75.98 per share. 31,683
05/04/2021 Lecointe Cephas Lisa
SVP Chief Ethics & Com Officer
694   Derivative/Non-derivative trans. at $75.98 per share. 52,730
05/03/2021 Rita A. Karachun
Sr. VP Fince-Global Controller
300   Derivative/Non-derivative trans. at $74.5 per share. 22,350
05/03/2021 Caroline A. Litchfield
EVP & CFO
353   Derivative/Non-derivative trans. at $74.5 per share. 26,298
05/03/2021 Dean Y. Li
Executive VP & President, MRL
257   Derivative/Non-derivative trans. at $74.5 per share. 19,146
05/03/2021 David Michael Williams
EVP,Chief Info&Digital Officer
142   Derivative/Non-derivative trans. at $74.5 per share. 10,579
05/03/2021 Lecointe Cephas Lisa
SVP Chief Ethics & Com Officer
150   Derivative/Non-derivative trans. at $74.5 per share. 11,175
05/03/2021 Rita A. Karachun
Sr. VP Fince-Global Controller
875   Derivative/Non-derivative trans. at $74.5 per share. 65,187
05/03/2021 Caroline A. Litchfield
EVP & CFO
750   Derivative/Non-derivative trans. at $74.5 per share. 55,875
05/03/2021 Dean Y. Li
Executive VP & President, MRL
750   Derivative/Non-derivative trans. at $74.5 per share. 55,875
05/03/2021 David Michael Williams
EVP,Chief Info&Digital Officer
412   Derivative/Non-derivative trans. at $74.5 per share. 30,694
05/03/2021 Lecointe Cephas Lisa
SVP Chief Ethics & Com Officer
437   Derivative/Non-derivative trans. at $74.5 per share. 32,556
05/01/2021 Rita A. Karachun
Sr. VP Fince-Global Controller
309   Derivative/Non-derivative trans. at $74.5 per share. 23,020
05/01/2021 Caroline A. Litchfield
EVP & CFO
288   Derivative/Non-derivative trans. at $74.5 per share. 21,456
05/01/2021 Dean Y. Li
Executive VP & President, MRL
354   Derivative/Non-derivative trans. at $74.5 per share. 26,373
05/01/2021 David Michael Williams
EVP,Chief Info&Digital Officer
192   Derivative/Non-derivative trans. at $74.5 per share. 14,304
05/01/2021 Lecointe Cephas Lisa
SVP Chief Ethics & Com Officer
210   Derivative/Non-derivative trans. at $74.5 per share. 15,645
05/01/2021 Rita A. Karachun
Sr. VP Fince-Global Controller
901   Derivative/Non-derivative trans. at $74.5 per share. 67,124
05/01/2021 Caroline A. Litchfield
EVP & CFO
840   Derivative/Non-derivative trans. at $74.5 per share. 62,580
05/01/2021 Dean Y. Li
Executive VP & President, MRL
1,030   Derivative/Non-derivative trans. at $74.5 per share. 76,735
05/01/2021 David Michael Williams
EVP,Chief Info&Digital Officer
560   Derivative/Non-derivative trans. at $74.5 per share. 41,720
05/01/2021 Lecointe Cephas Lisa
SVP Chief Ethics & Com Officer
622   Derivative/Non-derivative trans. at $74.5 per share. 46,339
02/26/2021 Kenneth C. Frazier
Chairman & CEO; Director
175,249   Award at $72.62 per share. 12,726,582
02/26/2021 Robert M. Davis
President
46,641   Award at $72.62 per share. 3,387,069
02/26/2021 Richard R. DeLuca
EVP&Pres, Merck Animal Heallth
25,510   Award at $72.62 per share. 1,852,536
02/26/2021 Franklin K. Clyburn
EVP & Pres ? Human Health
9,432   Award at $72.62 per share. 684,951
02/26/2021 Sanat Chattopadhyay
Exe V-P & Pres. MMD
25,772   Award at $72.62 per share. 1,871,562
02/26/2021 Julie Louise Gerberding
EVP Strat Comm, GI Pub Policy
12,585   Award at $72.62 per share. 913,922
02/26/2021 Rita A. Karachun
Sr. VP Fince-Global Controller
6,052   Award at $72.62 per share. 439,496
02/26/2021 Jennifer Zachary
EVP, General Counsel
24,199   Award at $72.62 per share. 1,757,331
02/26/2021 Steven C. Mizell
EVP, Chief HR Officer
17,830   Award at $72.62 per share. 1,294,814
02/26/2021 Michael T. Nally
EVP, Chief Marketing Officer
7,127   Award at $72.62 per share. 517,562
02/26/2021 Dean Y. Li
Executive VP & President, MRL
3,485   Award at $72.62 per share. 253,080
02/26/2021 Michael Fleming
SVP Chief Ethics & Com Officer
3,437   Award at $72.62 per share. 249,594
02/26/2021 David Michael Williams
EVP,Chief Info&Digital Officer
2,090   Award at $72.62 per share. 151,775
11/09/2020 Kenneth C. Frazier
Chairman & CEO; Director
144,866   Disposition at $81.74 per share. 11,841,346
11/09/2020 Kenneth C. Frazier
Chairman & CEO; Director
135,134   Disposition at $81.08 per share. 10,956,664
10/30/2020 Kenneth C. Frazier
Chairman & CEO; Director
64,073   Gift at $0 per share. 0
10/30/2020 Franklin K. Clyburn
EVP & Pres ? Human Health
1,137   Derivative/Non-derivative trans. at $75.89 per share. 86,286
10/30/2020 Steven C. Mizell
EVP, Chief HR Officer
2,273   Derivative/Non-derivative trans. at $75.89 per share. 172,497
10/30/2020 Michael T. Nally
EVP, Chief Marketing Officer
995   Derivative/Non-derivative trans. at $75.89 per share. 75,510
10/30/2020 Franklin K. Clyburn
EVP & Pres ? Human Health
2,287   Derivative/Non-derivative trans. at $75.89 per share. 173,560
10/30/2020 Steven C. Mizell
EVP, Chief HR Officer
4,574   Derivative/Non-derivative trans. at $75.89 per share. 347,120
10/30/2020 Michael T. Nally
EVP, Chief Marketing Officer
2,287   Derivative/Non-derivative trans. at $75.89 per share. 173,560
10/05/2020 Robert M. Davis
President
251,273   Disposition at $81.03 per share. 20,360,651
10/05/2020 Robert M. Davis
President
251,273   Derivative/Non-derivative trans. at $0 per share. 0
09/17/2020 Kenneth C. Frazier
Chairman & CEO; Director
15,500   Gift at $0 per share. 0
08/25/2020 Kenneth C. Frazier
Chairman & CEO; Director
12,500   Gift at $0 per share. 0
/news/latest/company/us/mrk

MarketWatch News on MRK

  1. Johnson & Johnson stock outperforms market on strong trading day

    4:32 p.m. Oct. 26, 2021

    - MarketWatch Automation

  2. Johnson & Johnson stock rises Monday, still underperforms market

    4:32 p.m. Oct. 25, 2021

    - MarketWatch Automation

  3. video content Perspectives on Prices from Beverly Hills to Europe

    8:00 a.m. Oct. 25, 2021

    - MarketBrief

  4. Merck and Ridgeback Biotherapeutics announce start of rolling review of COVID antiviral by EMA

    6:05 a.m. Oct. 25, 2021

    - Ciara Linnane

  5. Johnson & Johnson stock outperforms competitors on strong trading day

    4:32 p.m. Oct. 22, 2021

    - MarketWatch Automation

  6. Johnson & Johnson stock underperforms Thursday when compared to competitors

    4:32 p.m. Oct. 21, 2021

    - MarketWatch Automation

  7. Merck Scores Unexpectedly in Pneumococcal Vaccine Fight With Pfizer

    11:39 a.m. Oct. 21, 2021

    - Josh Nathan-Kazis

  8. Johnson & Johnson stock falls Wednesday, underperforms market

    4:32 p.m. Oct. 20, 2021

    - MarketWatch Automation

  9. Johnson & Johnson stock outperforms market on strong trading day

    4:32 p.m. Oct. 19, 2021

    - MarketWatch Automation

  10. Stocks Closed Up Today. Profits Are a Beautiful Thing.

    1:27 p.m. Oct. 19, 2021

    - Jack Denton

  11. Johnson & Johnson stock underperforms Monday when compared to competitors

    4:32 p.m. Oct. 18, 2021

    - MarketWatch Automation

  12. Johnson & Johnson stock rises Friday, still underperforms market

    4:32 p.m. Oct. 15, 2021

    - MarketWatch Automation

  13. Don't Count Out Covid-19 Monoclonal Antibody Treatments

    11:04 a.m. Oct. 15, 2021

    - Josh Nathan-Kazis

  14. Loading more headlines...
/news/nonmarketwatch/company/us/mrk

Other News on MRK

  1. Promising Covid-19 Pill Licensed to Nonprofit to Increase Global Supply

    34 min ago

    - Jared S. Hopkins

  2. Merck's HIV-1 drug combo maintains viral suppression at week 144 in mid-stage study

    7:08 a.m. Today

    - Seeking Alpha

  3. Merck inks voluntary licensing agreement for COVID-19 antiviral medicine molnupiravir

    6:11 a.m. Today

    - Seeking Alpha

  4. Novavax: Excellent Vaccine, Questionable Management

    7:09 p.m. Oct. 26, 2021

    - Seeking Alpha

  5. LeJeune Puetz Investment Counsel LLC Buys Victoria

    12:38 p.m. Oct. 26, 2021

    - GuruFocus.com

  6. 3 Top COVID Stocks -- Are They Tricks or Treats?

    7:00 a.m. Oct. 26, 2021

    - Motley Fool

  7. Was Atea Pharmaceutical's Flop Predictable?

    6:45 a.m. Oct. 26, 2021

    - Motley Fool

  8. Buy This Great High-Yield Dividend Stock?

    6:37 p.m. Oct. 25, 2021

    - Zacks.com

  9. Merck Vs. Pfizer: Which Healthcare Stock Is The Better Buy?

    1:51 p.m. Oct. 25, 2021

    - Seeking Alpha

  10. Merck (MRK) to Report Q3 Earnings: What's in the Cards?

    11:35 a.m. Oct. 25, 2021

    - Zacks.com

  11. Loading more headlines...

At a Glance

Merck & Co., Inc.

2000 Galloping Hill Road

Kenilworth, New Jersey 07033

Phone

1 9087404000

Industry

Pharmaceuticals

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2021

Revenue

$48.01B

Net Income

$7.07B

2020 Sales Growth

3.1%

Employees

74,000

/news/pressrelease/company/us/mrk

Press Releases on MRK

  1. Loading more headlines...
Trending Tickers
  • /zigman2/quotes/200467500/composite NVDA+6.20%
  • /zigman2/quotes/201948298/composite BABA-5.69%
  • /zigman2/quotes/202092269/composite ENSC+36.10%
  • /zigman2/quotes/200164174/composite SNOA+74.50%
  • /zigman2/quotes/207683784/composite TIGR-10.38%
X
Powered by StockTwits
Link to MarketWatch's Slice.